The YpsoDose patch injector platform will be offered as a fully integrated solution for the subcutaneous self-administration of large volume injectables
Ypsomed and ten23 health join forces to commercialise the YpsoDose patch injector. (Credit: Ypsomed AG)
Ypsomed has partnered with Swiss contract development and manufacturing organisation ten23 health to commercialise its YpsoDose large volume patch injector.
YpsoDose is designed to be a user-friendly patch injector for easy administration of drug volumes up to 10ml, featuring minimal usage steps. Its design and technical features are claimed to enable comfortable and safe injections in various conditions and environments, and are tailored to meet the formulation requirements.
The expertise of ten23 health in drug development, filling, and device assembly will support the product offering, said the Switzerland-based Ypsomed.
Under the partnership, both firms will make proactive investments in infrastructure and technology to provide the YpsoDose patch injector platform. It will be offered as a fully integrated solution for the subcutaneous self-administration of large volume injectables.
The integrated solution will include the YpsoDose patch injector platform and a ready-to-use cartriQ glass cartridge from Schott Pharma serving as the drug’s main packaging.
It will also include formulation and process development, filling, assembly, and quality control (QC) of the finished product by ten23 health.
According to Ypsomed, pharmaceutical customers will get a comprehensive solution that has undergone extensive testing and documentation, resulting in a faster time to clinic and time to market.
Ypsomed large volume injectors category lead Reto Jost said: “Together with ten23 as strong partner, we offer a comprehensive solution, for our customers to bring their medicines to market as a commercially viable and competitive product in a short time, at a lower cost and with low risks.”
In the collaboration, ten23 health will contribute its expertise in clinical and commercial fill and finish processes for complex dosage forms, including large volume device cartridges. Besides, the partnership will leverage ten23 health’s proficiency in developing, manufacturing, and testing intricate formulations for subcutaneous administration.
ten23 health chief enablement officer Hanns-Christian Mahler said: “This exciting partnership with Ypsomed aligns seamlessly with our vision of a successful drug product by which the drug-device integration is taken into account from the very beginning of its design – where formulation, primary packaging, and medical devices are an equally important part, providing stable, safe, usable and effective medicines to patients.”